NuProbe

VarMap® Pan-Cancer NGS Panel

2R-0501-S/2R-0501-M

Contact us for more information.

A 61-gene NGS panel that detects mutations down to 0.1% VAF.

  • ULTRASENSITIVE: Limit of detection down to 0.1% VAF
  • QUANTITATIVE: Quantify mutation VAF of samples down to 0.1% VAF
  • AFFORDABLE: Only 1 million reads per sample for liquid biopsy
  • VERSATILE: Compatible with several sample types
  • USER-FRIENDLY: Easy workflow and data analysis

For research use only. Not for use in diagnostic procedures.

The VarMap Pan-Cancer NGS Panel is the only liquid biopsy panel to detect 0.1% VAF on the MiniSeq and MiSeq requiring only 1M reads. It covers 337 hotspots in 61 genes with clinical high-significance in many cancer types and includes detection of over 6300 COSMIC mutations including JAK2 V617F, BRAF V600E, KRAS G12D/G12V/G12C, EGFR exon 19 deletions and insertions, EGFR T790M, EGFR L858R, and TP53 R248Q. Detecting these mutations simultaneously can provide a profile on patients’ carried mutations to apply targeted therapies accordingly. In addition, this ultra-sensitive assay offers an affordable way of monitoring post-treatment response.

The VarMap Pan-Cancer NGS Panel enables highly sensitive mutation detection and quantitation for cancer patients. The kit uses NuProbe’s PCR-based quantitative Blocker Displacement Amplification (qBDA) technology to enable the selective amplification of low abundant (≥0.1% VAF) sequence variants (SNV and indels) in a background of wildtype DNA. Next-generation sequencing of the PCR enriched samples enables accurate variant identification and variant allele frequency (VAF) quantitation. NuProbe’s technology significantly decreases the limit of detection (≥0.1% VAF) for NGS while decreasing the number of reads per sample 60-fold. Furthermore, the technology is compatible with a number of specimen types including cell-free DNA, tumor sections, and PMBC DNA. The kit’s sample versatility and increased sensitivity allow for a number of applications such as cell-free DNA profiling, minimal residual disease (MRD) monitoring and tumor heterogeneity characterization.

Benefits:

  • Comprehensive Cancer Mutation Panel: Detects and quantitates over 6300 mutations in the COSMIC database in 61 genes
  • Fast workflow: from DNA to library in 8 hours, including 3.5 hours of hands-on time
  • User-friendly data analysis software with graphical user interface enabling FASTQ-to-variant reports in minutes
  • Compatible with 20 ng cfDNA, gDNA (10ng/tube) and 40 ng FFPE DNA (20ng/tube)
  • Number of reads required per sample reduced to only 1 million reads, 60X less than standard deep sequencing

List of Genes and Mutations:

AKT1 ALK APC AR ATM BRAF CCND1
CDK4 CDKN2A CHEK2 CTNNB1 DDR2 EGFR ERBB2
ERBB3 ERBB4 ESR1 EZH2 FBXW7 FGFR1 FGFR2
FGFR3 FGFR4 FLT3 FOXL2 GNA11 GNAQ GNAS
HRAS IDH1 IDH2 JAK1 JAK2 JAK3 KIT
KRAS MAP2K1 MAP2K2 MET MLH1 MPL MTOR
MYC MYCN MYD88 NPM1 NRAS PDGFRA PIK3CA
PTEN PTPN11 RAF1 RB1 RET ROS1 SF3B1
SMAD4 SMARCB1 SMO STK11 TP53

 

NuProbe Product Page